SEC singles out Zai Lab, BeiGene, Hutchmed for regulatory scrutiny — with threats of delisting
Three of the most prominent drugmakers with roots in China — Zai Lab, BeiGene and Hutchmed — have been flagged by the SEC for failing to comply with a law governing US-listed companies.
In the worst case scenario, they could be delisted in 2024 and banned from American stock exchanges.
And they could just be the tip of the iceberg as tension between the US and China continues to brew. In statements responding to the SEC’s provisional list, all three companies suggest they expect more companies to come under regulatory scrutiny as they file their annual reports.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
